a

hus, we hypothesize that delivery of aerosolized regular blood glucose was evaluated. Mean blood glucose was significantly lower at 15, 30 and 45 min in the I25 and IV groups compared to baseline. Similarly, the IV and I25 groups had a significantly greater maximal percent change in blood glucose than the IS group. Significantly more cats developed severe hypoglycemia (<50 mg/dl; 2.7 mmol/l) in the IV and I25 groups than in the IS D e mon endocrinopathies in cats with one in 500 cats affected (Ettinger and Feld-jectable insulin therapy is the only effectivemeans idating or overly invasive for many cat owners tes mellitus. In January of 2006 the Food and Drug Administration announced approval of et al 1993, Jendle and Karlberg 1996, Perera et al 2006). Along with excellent efficacy, inhaled in-sulin is well tolerated by human patients with di-Journal of Feline Medicine and Surgery (2008) 10, 519e522 doi:10.1016/j.jfms.2008.04.008leading to a lack of compliance.of treatment (Martin and Rand 2000). Currently the administration of exogenous insulin involves subcutaneous injections one or more times daily (Martin and Rand 2000, Ettinger and Feldman 2005,Weaver et al 2006). This taskmayseem intim-2002, Hite et al 2006). In clinical studies, human diabetics have lower hemoglobin A1c concentra-tions, a marker of glycemic control, when treated with inhaled insulin compared to injectable forms of insulin (Laube et al 1993, Hite et alman 2005). Diabetes mellitus is characterized by a relative or absolute insulin deficiency leading to persistent hyperglycemia and glucosuria (Rand 1999). For many feline diabetic patients, in-the first inhaled insulin (Dunn and Curran 2006). Inhaled insulin is rapidly absorbed into the bloodstream and exerts metabolic effects in a similar manner to subcutaneous insulin (LaubePathobiology, University o